Ontology highlight
ABSTRACT: Aims
The study objective was to investigate the safety and tolerability of up-titration to high doses of taspoglutide, a once-weekly human glucagon-like peptide-1 analogue, in subjects with Type 2 diabetes inadequately controlled on metformin alone.Methods
In this double-blind phase II trial, subjects were randomized to placebo or taspoglutide (20 mg; three separate groups) administered once weekly by subcutaneous injection for 4 weeks. This was followed by dose maintenance at 20 mg, or titration to 30 mg (20/30) or 40 mg (20/40) once weekly with matched placebo for an additional 4 weeks. Subjects were monitored for adverse events (AEs) throughout the study and 4-week follow-up.Results
One hundred and twenty-nine subjects were randomized and treated [mean age 57 yea
SUBMITTER: Ratner R
PROVIDER: S-EPMC2948428 | biostudies-literature | 2010 May
REPOSITORIES: biostudies-literature